Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT04 vs Stelara in Moderate to Severe Plaque Psoriasis
NCT04930042Phase 3Completed
- Sponsor
- Alvotech
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of AVT04 in plaque psoriasis (2 arms), sponsored by Alvotech. Primary endpoint: Psoriasis Area and Severity Index at 12 weeks. Started Jun 2021; status: completed.
02
Drugs
AVT04
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04930042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930042.